These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6165189)

  • 1. Pharmacokinetic comparison of seven 8-methoxypsoralen brands.
    Menne T; Andersen KE; Larsen E; Solgaard P
    Acta Derm Venereol; 1981; 61(2):137-40. PubMed ID: 6165189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic comparison in dogs of seven brands of 8-MOP and five new formulations.
    Van Boven M; Roelandts R; De Greef H; Kinget R; Adriaens P; Daenens P
    Photodermatol; 1985 Feb; 2(1):27-31. PubMed ID: 3982992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
    Nørgaard M; Hueg B; Staberg B
    Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
    Tegeder I; Bräutigam L; Podda M; Meier S; Kaufmann R; Geisslinger G; Grundmann-Kollmann M
    Clin Pharmacol Ther; 2002 Mar; 71(3):153-61. PubMed ID: 11907489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.
    Thune P
    Acta Derm Venereol; 1978; 58(2):149-51. PubMed ID: 76395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
    Tanew A; Kipfelsperger T; Seeber A; Radakovic-Fijan S; Hönigsmann H
    J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
    Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
    Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and clinical comparison of two 8-methoxypsoralen brands.
    Andersen KE; Menne T; Gammeltoft M; Hjorth N; Larsen E; Solgaard P
    Arch Dermatol Res; 1980; 268(1):23-9. PubMed ID: 7416795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
    Engin B; Oguz O
    Int J Dermatol; 2005 Apr; 44(4):337-9. PubMed ID: 15811091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.
    Weber F; Schmuth M; Sepp N; Fritsch P
    Acta Derm Venereol; 2005; 85(4):329-32. PubMed ID: 16191854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoralen cream plus ultraviolet A photochemotherapy (PUVA cream): our experience.
    Pozo-Román T; González-López A; Velasco-Vaquero ME; Núñez-Cabezón M
    J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):136-42. PubMed ID: 16441619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of a new oral methoxsalen formulation. A serum concentration and photosensitivity response study.
    Sullivan TJ; Walter JL; Kouba RF; Maiwald DC
    Arch Dermatol; 1986 Jul; 122(7):768-71. PubMed ID: 3729509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
    Man I; McKinlay J; Dawe RS; Ferguson J; Ibbotson SH
    J Am Acad Dermatol; 2003 Jul; 49(1):59-64. PubMed ID: 12833009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of serum levels for three oral 8-methoxypsoralen brands.
    Walther T; Quednow B; Haustein UF; Meyer FP
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):1-3. PubMed ID: 1390116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.
    Tzaneva S; Kittler H; Thallinger C; Hönigsmann H; Tanew A
    Photodermatol Photoimmunol Photomed; 2009 Apr; 25(2):101-5. PubMed ID: 19292787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 8-Methoxypsoralen plasma levels and phototoxic effect.
    De Bersaques J; Monbaliu J; Belpaire F; Bogaert M
    Photodermatol; 1984 Apr; 1(2):79-84. PubMed ID: 6531285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
    Herfst MJ; De Wolff FA
    Br J Clin Pharmacol; 1982 Apr; 13(4):519-22. PubMed ID: 7066167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of 8-methoxypsoralen following oral or bath-water treatment.
    Thomas SE; O'Sullivan J; Balac N
    Br J Dermatol; 1991 Jul; 125(1):56-8. PubMed ID: 1873204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
    Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.